» Articles » PMID: 7528766

Mouse Complement Regulatory Protein Crry/p65 Uses the Specific Mechanisms of Both Human Decay-accelerating Factor and Membrane Cofactor Protein

Overview
Journal J Exp Med
Date 1995 Jan 1
PMID 7528766
Citations 80
Authors
Affiliations
Soon will be listed here.
Abstract

Normal host cells are protected from the destructive action of complement by cell surface complement regulatory proteins. In humans, decay-accelerating factor (DAF) and membrane cofactor protein (MCP) play such a biologic role by inhibiting C3 and C5 convertases. DAF and MCP accomplish this task by specific mechanisms designated decay-accelerating activity and factor I cofactor activity, respectively. In other species, including mice, structural and/or functional homologues of these proteins are not yet well characterized. Previous studies have shown that the mouse protein Crry/p65 has certain characteristics of self-protecting complement regulatory proteins. For example, Crry/p65 is expressed on a wide variety of murine cells, and when expressed on human K562 erythroleukemic cells, it prevents deposition of mouse C3 fragments on the cell surface during activation of either the classical or alternative complement pathway. We have now studied factor I cofactor and decay-accelerating activities of Crry/p65. Recombinant Crry/p65 demonstrates cofactor activity for factor I-mediated cleavage of both mouse C3b and C4b. Surprisingly, Crry/p65 also exhibits decay-accelerating activity for the classical pathway C3 convertase strongly and for the alternative pathway C3 convertase weakly. Therefore, mouse Crry/p65 uses the specific mechanisms of both human MCP and DAF. Although Crry/p65, like MCP and DAF, contains tandem short consensus repeats (SCR) characteristic of C3/C4 binding proteins, Crry/p65 is not considered to be a genetic homologue of either MCP or DAF. Thus, Crry/p65 is an example of evolutionary conservation of two specific activities in a single unique protein in one species that are dispersed to individual proteins in another. We propose that the repeating SCR motif in this family has allowed this unusual process of evolution to occur, perhaps driven by the use of MCP and DAF as receptors by human pathogens such as the measles virus.

Citing Articles

A Monocytic Barrier to the Humanization of Immunodeficient Mice.

Du E, Muench M Curr Stem Cell Res Ther. 2023; 19(7):959-980.

PMID: 37859310 PMC: 10997744. DOI: 10.2174/011574888X263597231001164351.


Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins.

Li Y, Jacques S, Gaikwad H, Wang G, Banda N, Holers V Nat Nanotechnol. 2023; 19(2):246-254.

PMID: 37798566 PMC: 11034866. DOI: 10.1038/s41565-023-01514-z.


Alternative pathway activation in pregnancy, a measured amount "complements" a successful pregnancy, too much results in adverse events.

Smith-Jackson K, Harrison R Immunol Rev. 2022; 313(1):298-319.

PMID: 36377667 PMC: 10100418. DOI: 10.1111/imr.13169.


Contribution of animal models to the mechanistic understanding of Alternative Pathway and Amplification Loop (AP/AL)-driven Complement-mediated Diseases.

Gibson B, Cox T, Marchbank K Immunol Rev. 2022; 313(1):194-216.

PMID: 36203396 PMC: 10092198. DOI: 10.1111/imr.13141.


Development and Optimization of Bifunctional Fusion Proteins to Locally Modulate Complement Activation in Diseased Tissue.

Fahnoe K, Liu F, Morgan J, Ryan S, Storek M, Stark E Front Immunol. 2022; 13:869725.

PMID: 35784298 PMC: 9244803. DOI: 10.3389/fimmu.2022.869725.


References
1.
Nowicki B, Hart A, Coyne K, Lublin D, Nowicki S . Short consensus repeat-3 domain of recombinant decay-accelerating factor is recognized by Escherichia coli recombinant Dr adhesin in a model of a cell-cell interaction. J Exp Med. 1993; 178(6):2115-21. PMC: 2191283. DOI: 10.1084/jem.178.6.2115. View

2.
Davitz M, Low M, NUSSENZWEIG V . Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein. J Exp Med. 1986; 163(5):1150-61. PMC: 2188092. DOI: 10.1084/jem.163.5.1150. View

3.
Kalli K, Fearon D . Binding of C3b and C4b by the CR1-like site in murine CR1. J Immunol. 1994; 152(6):2899-903. View

4.
Takizawa H, Okada N, Okada H . Complement inhibitor of rat cell membrane resembling mouse Crry/p65. J Immunol. 1994; 152(6):3032-8. View

5.
Morgan B, Meri S . Membrane proteins that protect against complement lysis. Springer Semin Immunopathol. 1994; 15(4):369-96. DOI: 10.1007/BF01837366. View